Development of morbidity and mortality in ANCA-associated vasculitis

The outcome of ANCA (antineutrophil cytoplasmic antibody)-associated vasculitis (AAV) has been significantly improved due to the combined use of cyclophosphamide (CYC) and glucocorticosteroids. Recent studies demonstrated a normalization of life expectancy for several subgroups of AAV patients. Mort...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Zeitschrift für Rheumatologie 2011-08, Vol.70 (6), p.486
Hauptverfasser:	Reinhold-Keller, E, Moosig, F
Format:	Artikel
Sprache:	ger
Schlagworte:	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - diagnosis Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - mortality Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cause of Death Churg-Strauss Syndrome - diagnosis Churg-Strauss Syndrome - drug therapy Churg-Strauss Syndrome - mortality Cyclophosphamide - adverse effects Cyclophosphamide - therapeutic use Glucocorticoids - adverse effects Glucocorticoids - therapeutic use Granulomatosis with Polyangiitis - diagnosis Granulomatosis with Polyangiitis - drug therapy Granulomatosis with Polyangiitis - mortality Humans Neoplasms - chemically induced Neoplasms - mortality Neoplasms - prevention & control Opportunistic Infections - mortality Opportunistic Infections - prevention & control Risk Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!